Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:PFSCFNYSE:PLXOTCMKTS:PVCTNASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/APLXProtalix BioTherapeutics$1.49-3.2%$2.13$0.82▼$3.10$118.61M-0.21558,494 shs500,745 shsPVCTProvectus Biopharmaceuticals$0.07-3.4%$0.09$0.04▼$0.17$30.98M0.78201,019 shs186,536 shsSGMTSagimet Biosciences$8.27-3.9%$3.54$1.73▼$9.60$253.68M2.211.03 million shs5.29 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%PLXProtalix BioTherapeutics0.00%-5.70%-10.78%-33.48%+25.74%PVCTProvectus Biopharmaceuticals0.00%-1.73%-11.20%-27.25%-53.94%SGMTSagimet Biosciences0.00%+48.74%+149.85%+121.12%+54.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPFSCFProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics2.5915 of 5 stars3.54.00.00.00.60.01.9PVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASGMTSagimet Biosciences2.3369 of 5 stars3.42.00.00.03.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePFSCFProMetic Life Sciences 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00906.71% UpsidePVCTProvectus Biopharmaceuticals 0.00N/AN/AN/ASGMTSagimet Biosciences 2.83Moderate Buy$23.17180.13% UpsideCurrent Analyst Ratings BreakdownLatest PVCT, PFSCF, PLX, and SGMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025SGMTSagimet BiosciencesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $27.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08PLXProtalix BioTherapeutics$59.76M1.98$0.08 per share17.80$0.47 per share3.17PVCTProvectus Biopharmaceuticals$560K55.31N/AN/A($0.02) per share-3.69SGMTSagimet Biosciences$2M126.84N/AN/A$3.98 per share2.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.81N/A-21.03%-30.89%-11.74%N/APVCTProvectus Biopharmaceuticals-$3.10MN/A0.00∞N/A-418.23%N/A-289.35%8/11/2025 (Estimated)SGMTSagimet Biosciences-$27.88M-$1.76N/AN/AN/AN/A-23.63%-22.91%8/13/2025 (Estimated)Latest PVCT, PFSCF, PLX, and SGMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/A5/8/2025Q1 2025SGMTSagimet Biosciences-$0.79-$0.56+$0.23-$0.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPFSCFProMetic Life SciencesN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPFSCFProMetic Life SciencesN/A0.950.71PLXProtalix BioTherapeuticsN/A1.981.27PVCTProvectus BiopharmaceuticalsN/A0.120.12SGMTSagimet BiosciencesN/A38.4138.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPFSCFProMetic Life Sciences0.10%PLXProtalix BioTherapeutics16.53%PVCTProvectus Biopharmaceuticals0.05%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipPFSCFProMetic Life SciencesN/APLXProtalix BioTherapeutics6.50%PVCTProvectus Biopharmaceuticals14.70%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePFSCFProMetic Life Sciences5023.31 millionN/ANot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionablePVCTProvectus Biopharmaceuticals4420.28 million366.48 millionNot OptionableSGMTSagimet Biosciences830.68 million25.28 millionOptionablePVCT, PFSCF, PLX, and SGMT HeadlinesRecent News About These CompaniesSagimet Biosciences Inc.June 14 at 6:16 PM | wsj.comTwo Sigma Investments LP Trims Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)June 12 at 3:27 AM | marketbeat.comSagimet Biosciences updates executive compensationJune 12 at 1:48 AM | investing.comWhat Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?June 11, 2025 | zacks.comAnalysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) Price Target at $23.17June 11, 2025 | americanbankingnews.comSagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to ...June 11, 2025 | morningstar.comWall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should KnowJune 9, 2025 | zacks.comSagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025June 9, 2025 | globenewswire.comSagimet Biosciences (NASDAQ:SGMT) Price Target Raised to $27.00June 9, 2025 | americanbankingnews.comReviewing Sagimet Biosciences (SGMT) & The CompetitionJune 7, 2025 | americanbankingnews.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 6, 2025 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Price Target Raised to $27.00 at Jones TradingJune 6, 2025 | marketbeat.comSagimet Biosciences Analyst RatingsJune 5, 2025 | benzinga.comSagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne TreatmentJune 4, 2025 | marketwatch.comSagimet Biosciences shares soar on positive acne treatment trial resultsJune 4, 2025 | ca.investing.comSagimet partner Ascletis announces significant Phase III acne dataJune 4, 2025 | thepharmaletter.comSagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug ResultsJune 4, 2025 | msn.comSagimet climbs as acne therapy hits main goals in late-stage trial in ChinaJune 4, 2025 | msn.comSagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock JumpsJune 4, 2025 | aol.comSagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567June 4, 2025 | seekingalpha.comSagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner AscletisJune 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePVCT, PFSCF, PLX, and SGMT Company DescriptionsProMetic Life Sciences OTCMKTS:PFSCF$5.47 0.00 (0.00%) As of 11/18/2019Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Protalix BioTherapeutics NYSE:PLX$1.49 -0.05 (-3.25%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.51 +0.02 (+1.34%) As of 06/13/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Provectus Biopharmaceuticals OTCMKTS:PVCT$0.07 0.00 (-3.41%) As of 06/13/2025 02:29 PM EasternProvectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.Sagimet Biosciences NASDAQ:SGMT$8.27 -0.34 (-3.95%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.27 0.00 (0.00%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
